

Michael E Klepser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11202071/publications.pdf>

Version: 2024-02-01

43
papers

2,837
citations

201385

27
h-index

264894

42
g-index

43
all docs

43
docs citations

43
times ranked

1938
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of aerosolized amphotericin B. Expert Opinion on Drug Safety, 2007, 6, 523-532.	1.0	478
2	Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods. Antimicrobial Agents and Chemotherapy, 1998, 42, 1207-1212.	1.4	260
3	Unsafe and potentially safe herbal therapies. American Journal of Health-System Pharmacy, 1999, 56, 125-138.	0.5	175
4	Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> . Antimicrobial Agents and Chemotherapy, 2000, 44, 1108-1111.	1.4	175
5	In Vitro Activity of Micafungin (FK-463) against <i>Candida</i> spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies. Antimicrobial Agents and Chemotherapy, 2002, 46, 3846-3853.	1.4	146
6	In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagnostic Microbiology and Infectious Disease, 1999, 33, 75-80.	0.8	140
7	In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against <i>Aspergillus</i> , <i>Fusarium</i> , and <i>Scedosporium</i> spp. Antimicrobial Agents and Chemotherapy, 2005, 49, 945-951.	1.4	111
8	Assessment of Patients' Perceptions and Beliefs Regarding Herbal Therapies. Pharmacotherapy, 2000, 20, 83-87.	1.2	110
9	Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology. Antimicrobial Agents and Chemotherapy, 2000, 44, 1917-1920.	1.4	101
10	Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> via time-kill methods. Diagnostic Microbiology and Infectious Disease, 2002, 43, 13-17.	0.8	94
11	Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination against <i>Candida albicans</i> by Using a Dynamic In Vitro Mycotic Infection Model. Antimicrobial Agents and Chemotherapy, 1998, 42, 1382-1386.	1.4	87
12	Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Pharmacotherapy, 2010, 30, 562-584.	1.2	77
13	Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against <i>Candida</i> spp.. Diagnostic Microbiology and Infectious Disease, 1996, 26, 125-131.	0.8	70
14	Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?. American Journal of Health-System Pharmacy, 1997, 54, 2569-2584.	0.5	62
15	Drug Treatment of HIV-Related Opportunistic Infections. Drugs, 1997, 53, 40-73.	4.9	56
16	Antifungal Resistance Among <i>Candida</i> Species. Pharmacotherapy, 2001, 21, 124S-132S.	1.2	50
17	Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. Research in Social and Administrative Pharmacy, 2018, 14, 356-359.	1.5	50
18	Rates and Extents of Antifungal Activities of Amphotericin B, Flucytosine, Fluconazole, and Voriconazole against <i>Candida lusitanae</i> Determined by Microdilution, Etest, and Time-Kill Methods. Antimicrobial Agents and Chemotherapy, 2002, 46, 578-581.	1.4	48

#	ARTICLE	IF	CITATIONS
19	Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against <i>Streptococcus pneumoniae</i> in a Dynamic In Vitro Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 673-678.	1.4	47
20	Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1387-1391.	1.4	43
21	Candida Resistance and Its Clinical Relevance. <i>Pharmacotherapy</i> , 2006, 26, 68S-75S.	1.2	43
22	In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 36, 101-105.	0.8	40
23	The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 525-533.	0.5	37
24	In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2887-2890.	1.4	37
25	Evaluation of amphotericin B and flucytosine in combination against <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> using time-kill methodology. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 41, 121-126.	0.8	36
26	The Rationale for Aerosolized Antibiotics. <i>Pharmacotherapy</i> , 2002, 22, 71S-79S.	1.2	34
27	U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 614-621.	1.5	33
28	Variation in Electrophoretic Karyotype and Antifungal Susceptibility of Clinical Isolates of <i>Cryptococcus neoformans</i> at a University-Affiliated Teaching Hospital from 1987 to 1994. <i>Journal of Clinical Microbiology</i> , 1998, 36, 3653-3656.	1.8	25
29	Growth medium effect on the antifungal activity of LY 303366. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 29, 227-231.	0.8	23
30	Therapy of Candidal Infections: Susceptibility Testing, Resistance, and Therapeutic Options. <i>Annals of Pharmacotherapy</i> , 1998, 32, 1353-1361.	0.9	20
31	Pharmacy-based management of influenza: lessons learned from research. <i>International Journal of Pharmacy Practice</i> , 2018, 26, 573-578.	0.3	19
32	Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1574-1578.	1.5	18
33	Observation of a Pharmacist-Conducted Group A Streptococcal Pharyngitis Point-of-Care Test: A Time and Motion Study. <i>Journal of Pharmacy Practice</i> , 2018, 31, 284-291.	0.5	17
34	Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 112-115.	1.5	13
35	Point-of-care testing in the pharmacy: how is the field evolving?. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 5-6.	1.5	12
36	The Roles of Pharmacy Schools in Bridging the Gap Between Law and Practice. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6577.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Pharmacy-Based Assessment and Management of Herpes Labialis (Cold Sores) with Antiviral Therapy. <i>Innovations in Pharmacy</i> , 2020, 11, 3.	0.2	10
38	An update on community pharmacies as CLIA-waived facilities. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 666-667.	1.5	9
39	Pharmacist Prescriptive Authority for Acne: An Evidence-Based Approach to Policy. <i>Innovations in Pharmacy</i> , 2021, 12, 11.	0.2	9
40	Amphotericin B in Lung Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 2002, 36, 167-169.	0.9	8
41	The impact of the COVID-19 pandemic on addressing common barriers to pharmacy-based point-of-care testing. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 751-755.	1.5	3
42	Safety and Efficacy Data for High-Dose Caspofungin. <i>Current Fungal Infection Reports</i> , 2010, 4, 59-61.	0.9	1
43	Pharmacological and Host Considerations in the Selection of Dose and Duration of Azole Therapy for Adult Patients. <i>Current Fungal Infection Reports</i> , 2012, 6, 127-132.	0.9	0